KAN — Kancera AB Share Price
0.000.00%
Last trade - 00:00- SEK230.46m
- SEK172.24m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.6 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.83 | ||
| Price to Tang. Book | 7.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -136.46% | ||
| Return on Equity | -83.96% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 3.22 | 0.09 | n/a | n/a | n/a | 61.3 | 59.1 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +150.26 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
Directors
- Erik Nerpin NEC (58)
- Thomas Olin CEO (60)
- Hans Richter CFO (72)
- Martin Norin COO (58)
- Niclas Brynne MGB (60)
- Torbjorn Lundstrom MGB (68)
- Johan Schultz MGB (61)
- Charlotte Edenius IND (63)
- Anders Gabrielsen IND (55)
- Carl-Henrik Heldin IND (65)
- Hakan Mellstedt IND (75)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 31st, 2010
- Public Since
- February 21st, 2011
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 147,729,260
- Address
- Karolinska Institutet Science Park, SOLNA, 171 65
- Web
- https://kancera.com/
- Phone
- +46 850126080
- Contact
- Thomas Olin
- Auditors
- Grant Thornton Sweden AB
Upcoming Events for KAN
Kancera AB Annual Shareholders Meeting
Q2 2024 Kancera AB Earnings Release
Similar to KAN
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Kancera AB share price?
As of Today at 19:12 UTC, shares in Kancera AB are trading at SEK1.56. This share price information is delayed by 15 minutes.
How has the Kancera AB share price performed this year?
Shares in Kancera AB last closed at SEK1.56 and the price had moved by -52.12% over the past 365 days. In terms of relative price strength the Kancera AB share price has underperformed the FTSE Global All Cap Index by -55.83% over the past year.
What are the analyst and broker recommendations for Kancera AB?
There is no consensus recommendation for this security.
What is the Kancera AB dividend yield?
Kancera AB does not currently pay a dividend.
Does Kancera AB pay a dividend?
Kancera AB does not currently pay a dividend.
When does Kancera AB next pay dividends?
Kancera AB does not currently pay a dividend.
How do I buy Kancera AB shares?
To buy shares in Kancera AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kancera AB?
As of the previous close price of SEK1.56, shares in Kancera AB had a market capitalisation of SEK230.46m.
Where are Kancera AB shares listed?
Here are the trading details for Kancera AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: KAN
What kind of share is Kancera AB?
Based on an overall assessment of its quality, value and momentum Kancera AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kancera AB share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Kancera AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kancera AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -67.94%.
As of the last closing price of SEK1.56, shares in Kancera AB were trading -59.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kancera AB PE Ratio?
The Kancera AB PE ratio based on its reported earnings over the past 12 months is 5.6. The shares last closed at SEK1.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kancera AB?
Kancera AB's management team is headed by:
- Erik Nerpin - NEC
- Thomas Olin - CEO
- Hans Richter - CFO
- Martin Norin - COO
- Niclas Brynne - MGB
- Torbjorn Lundstrom - MGB
- Johan Schultz - MGB
- Charlotte Edenius - IND
- Anders Gabrielsen - IND
- Carl-Henrik Heldin - IND
- Hakan Mellstedt - IND